Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Collaborator: Daewoong Pharmaceutical Co. LTD.
• Treatments: Evolocumab; Ezetimibe; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

1. Over 19 years old

2. Patients who agreed to the research protocol and clinical follow-up survey plan, decided to participate in this study voluntarily, and gave written consent to the informed consent form.

3. Patients who underwent percutaneous coronary stenting for acute coronary syndrome

Exclusion Criteria:

1. Patients who have previously taken statins,

2. Patients with active liver disease or patients with three times or more increase in AST or ALT

3. If you have an allergic or hypersensitivity reaction to Evorucumab, statin, or Ezetimib,

4. Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study

5. The remaining life expectancy is expected to be less than a year.

6. Subjects who visited the hospital due to psychogenic shock and are expected to be less likely to survive by medical judgment

7. Subjects participating in a randomized clinical trial of medical devices/pharmaceuticals